Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity

Cancer Research

Volumn 61, Issue 7, 2001, Pages 3077-3083

  Eck, S C ^a   Turka, L A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; HEMAGGLUTININ; IMMUNOGLOBULIN G;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TRANSGENE; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIGENS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; INFLUENZA A VIRUS; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC;

EID: 0035300469     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cancer antigens: Immune recognition of self and altered self
2. A new era for cancer immunotherapy based on the genes that encode cancer antigens
3. The shared tumor-specific antigen encoded by mouse gene PlA is a target not only for cytolytic T lymphocytes but also for tumor rejection
4. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
5. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
6. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
7. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity
8. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
9. + T lymphocytes
10. Coupling and uncoupling of tumor immunity and autoimmunity
11. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
12. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
13. p53: A potential target antigen for immunotherapy of cancer
14. Targeting p53 as a general tumor antigen
15. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
16. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
17. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
18. + T cells
19. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
20. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors
21. + T cells have a major "post-licensing" role in CTL-mediated antitumor immunity
22. + T cells
23. Transgenic mice that express different forms of the influenza virus hemagglutinin as a neo-self-antigen
24. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice
25. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF
26. Disquisitions of original antigenic sin. I. Evidence in man
27. Activation and negative selection of functionally distinct subsets of antibody-secreting cells by influenza hemagglutinin as a viral and a neo-self antigen
28. An innate sense of danger
29. + T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas
30. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
31. Endogenous myelin basic protein inactivates the high avidity T cell repertoire
32. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
33. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
34. Peripheral selection of the T cell repertoire
35. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
36. + T cell tolerance induction versus priming is independent of the rate and number of cell divisions
37. + T cell tolerance to peripherally expressed antigens